NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Supernus Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Supernus Pharmaceuticals is a biopharmaceutical company that markets approved medications for central nervous system disorders including attention-deficit hyperactivity disorder, Parkinson's Disease motor complications, postpartum depression, seizures, migraine prevention, cervical dystonia, and excessive salivation. The company also maintains a pipeline of product candidates in development for various neurological and psychiatric conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Supernus Inc stock.
Overvalued: intrinsic value $7.92 per share, market price $29.04, margin of safety -266.5% (as of 2026-11-17).
Its through-the-cycle earnings (14.5% median margin), capitalised at 10.2% with no growth, values the shares at $7.92; the price of $29.04 is 267% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
27 more in this industry show a wider margin of safety.
SUPN is overvalued (as of the 2026-11-17 close). Its through-the-cycle earnings (14.5% median margin), capitalised at 10.2% with no growth, values the shares at $7.92; the price of $29.04 is 267% above that value.
$7.92 per share (as of the 2026-11-17 close), against a market price of $29.04. That is a margin of safety of -266.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.